NCT06462794View on ClinicalTrials.gov

First In Human Study of CX-801 in Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

August 28, 2024

Primary Completion Date

February 28, 2028

Study Completion Date

June 30, 2029

Conditions
Solid Tumor, Adult
Interventions
DRUG

CX-801

Investigational drug

DRUG

pembrolizumab

Standard of Care Therapy

Trial Locations (2)

15232

RECRUITING

University of Pittsburgh Hillman Cancer Center, Pittsburgh

94158

NOT_YET_RECRUITING

University of California San Francisco, San Francisco

Sponsors
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

CytomX Therapeutics

INDUSTRY

NCT06462794 - First In Human Study of CX-801 in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter